Compare Lupin Ltd with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN vs GSK PHARMA - Comparison Results

LUPIN     Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN GSK PHARMA LUPIN/
GSK PHARMA
 
P/E (TTM) x 48.6 51.4 94.4% View Chart
P/BV x 2.5 10.8 23.0% View Chart
Dividend Yield % 0.0 1.5 -  

Financials

 LUPIN   GSK PHARMA
EQUITY SHARE DATA
    LUPIN
Mar-19
GSK PHARMA
Mar-19
LUPIN/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs9863,595 27.4%   
Low Rs7201,253 57.5%   
Sales per share (Unadj.) Rs369.5184.7 200.1%  
Earnings per share (Unadj.) Rs13.426.3 51.0%  
Cash flow per share (Unadj.) Rs37.429.2 128.2%  
Dividends per share (Unadj.) Rs020.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs303.7126.3 240.4%  
Shares outstanding (eoy) m452.49169.40 267.1%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.313.1 17.6%   
Avg P/E ratio x63.692.2 69.0%  
P/CF ratio (eoy) x22.883.1 27.5%  
Price / Book Value ratio x2.819.2 14.6%  
Dividend payout %076.1 0.0%   
Avg Mkt Cap Rs m386,064410,626 94.0%   
No. of employees `00017.75.0 356.5%   
Total wages/salary Rs m31,5135,372 586.6%   
Avg. sales/employee Rs Th9,453.86,306.7 149.9%   
Avg. wages/employee Rs Th1,782.01,083.1 164.5%   
Avg. net profit/employee Rs Th343.0898.0 38.2%   
INCOME DATA
Net Sales Rs m167,18231,281 534.4%  
Other income Rs m3,6401,023 355.8%   
Total revenues Rs m170,82232,304 528.8%   
Gross profit Rs m28,8226,009 479.7%  
Depreciation Rs m10,850486 2,232.5%   
Interest Rs m3,0786 51,305.0%   
Profit before tax Rs m18,5346,540 283.4%   
Minority Interest Rs m-890-   
Prior Period Items Rs m380-   
Extraordinary Inc (Exp) Rs m-3,400287 -1,184.6%   
Tax Rs m9,0172,373 380.0%   
Profit after tax Rs m6,0664,454 136.2%  
Gross profit margin %17.219.2 89.7%  
Effective tax rate %48.736.3 134.1%   
Net profit margin %3.614.2 25.5%  
BALANCE SHEET DATA
Current assets Rs m138,53620,061 690.6%   
Current liabilities Rs m61,29914,543 421.5%   
Net working cap to sales %46.217.6 261.9%  
Current ratio x2.31.4 163.8%  
Inventory Days Days8457 147.6%  
Debtors Days Days11214 799.6%  
Net fixed assets Rs m127,51614,343 889.1%   
Share capital Rs m9051,694 53.4%   
"Free" reserves Rs m136,51719,704 692.8%   
Net worth Rs m137,42221,398 642.2%   
Long term debt Rs m66,4172 3,320,860.0%   
Total assets Rs m279,49439,113 714.6%  
Interest coverage x7.01,091.0 0.6%   
Debt to equity ratio x0.50 517,097.5%  
Sales to assets ratio x0.60.8 74.8%   
Return on assets %3.311.4 28.7%  
Return on equity %4.420.8 21.2%  
Return on capital %8.931.9 27.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m59,414534 11,126.1%   
Fx outflow Rs m22,2827,091 314.2%   
Net fx Rs m37,132-6,557 -566.3%   
CASH FLOW
From Operations Rs m16,6603,994 417.1%  
From Investments Rs m-32,825-1,433 2,290.0%  
From Financial Activity Rs m7,441-3,584 -207.6%  
Net Cashflow Rs m-8,724-1,023 852.6%  

Share Holding

Indian Promoters % 46.6 0.0 -  
Foreign collaborators % 0.2 50.7 0.4%  
Indian inst/Mut Fund % 11.3 10.2 110.8%  
FIIs % 31.9 23.8 134.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 15.4 65.6%  
Shareholders   98,259 102,036 96.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN With:   STRIDES PHARMA SCIENCE  AJANTA PHARMA  UNICHEM LAB  DR. DATSONS LABS  ELDER PHARMA  

Compare LUPIN With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Downtrend, Developments From the IPO Space, and Top Cues in Focus Today(Pre-Open)

On Tuesday, Indian share markets fell sharply during closing hours amid fears of rising crude oil prices and weakness in the rupee.

Related Views on News

LUPIN Announces Quarterly Results (1QFY20); Net Profit Up 49.3% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, LUPIN has posted a net profit of Rs 3 bn (up 49.3% YoY). Sales on the other hand came in at Rs 44 bn (up 14.6% YoY). Read on for a complete analysis of LUPIN's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 28.1% (Quarterly Result Update)

Jul 24, 2019 | Updated on Jul 24, 2019

For the quarter ended June 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 28.1% YoY). Sales on the other hand came in at Rs 8 bn (up 7.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

LUPIN 2018-19 Annual Report Analysis (Annual Result Update)

Jul 18, 2019 | Updated on Jul 18, 2019

Here's an analysis of the annual report of LUPIN for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

GSK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.

GSK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 16.6% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 16.6% YoY). Sales on the other hand came in at Rs 8 bn (up 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN SHARE PRICE


Sep 17, 2019 (Close)

TRACK LUPIN

COMPARE LUPIN WITH

MARKET STATS